Novartis develops and manufactures innovative drugs... Show more
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where NVS advanced for three days, in 182 of 339 cases, the price rose further within the following month. The odds of a continued upward trend are 54%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where NVS's RSI Indicator exited the oversold zone, 9 of 24 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 38%.
The Momentum Indicator moved above the 0 level on September 22, 2026. You may want to consider a long position or call options on NVS as a result. In 44 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 52%.
NVS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The Moving Average Convergence Divergence Histogram (MACD) for NVS turned negative on September 08, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 19 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 42%.
NVS moved below its 50-day moving average on September 08, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for NVS crossed bearishly below the 50-day moving average on September 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 56%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NVS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 43%.
The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.464) is normal, around the industry mean (19.154). P/E Ratio (21.341) is within average values for comparable stocks, (34.694). Projected Growth (PEG Ratio) (3.310) is also within normal values, averaging (5.619). Dividend Yield (0.034) settles around the average of (0.025) among similar stocks. P/S Ratio (4.715) is also within normal values, averaging (4.033).
The Tickeron Profit vs. Risk Rating rating for this company is 12 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 63, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 25 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 33 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating fairly steady price growth. NVS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a manufacturer of health care and nutritional products
Industry PharmaceuticalsMajor